Tags

Type your tag names separated by a space and hit enter

The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.
Osteoporos Int. 2010 Feb; 21(2):339-49.OI

Abstract

The cost-effectiveness of strontium ranelate was compared to no treatment in UK women using the FRAX algorithm for fracture risk assessment. At a willingness-to-pay of pound 30,000 per quality-adjusted life-year (QALY), strontium ranelate was generally cost-effective in women with prior fracture at the threshold of osteoporosis from an age of 65 years.

INTRODUCTION

The objectives of the study were to estimate the cost-effectiveness of strontium ranelate in the UK for the treatment of osteoporosis and to establish intervention thresholds for treatment using the FRAX tool.

METHODS

The cost-effectiveness of strontium ranelate was compared to no treatment in postmenopausal women with clinical risk factors for fracture using a lifetime simulation model based on Markov cohort methodology that incorporated the features of FRAX.

RESULTS

At a threshold of pound 30,000 per QALY, strontium ranelate was generally cost-effective in women from an age of 65 years with prior fracture at the threshold of osteoporosis (i.e., a T-score of -2.5 SD) and in women with a prior fracture (and no information on bone mineral density) from the age of 65 years. At a threshold of pound 20,000, strontium ranelate became cost-effective at a 10-year fracture probability of 25.7% and at 16.9% with a threshold of pound 30,000 for a QALY.

CONCLUSIONS

Strontium ranelate is a cost-effective agent for the treatment of established osteoporosis in women over the age of 65 years. Cost-effective scenarios were also found for the prevention and treatment of fractures associated with osteoporosis, in younger women with additional clinical risk factors.

Links

Aggregator Full Text

Authors+Show Affiliations

Borgström F
Medical Management Centre, Karolinska Institute, Stockholm, Sweden. fredrik.borgstrom@i3innovus.com
Ström O
No affiliation info available
Coelho J
No affiliation info available
Johansson H
No affiliation info available
Oden A
No affiliation info available
McCloskey E
No affiliation info available
Kanis JA
No affiliation info available

MeSH

Age FactorsAgedAged, 80 and overAlgorithmsBone Density Conservation AgentsCost-Benefit AnalysisDrug CostsEpidemiologic MethodsFemaleHealth Care CostsHumansMiddle AgedOrganometallic CompoundsOsteoporosis, PostmenopausalOsteoporotic FracturesQuality of LifeQuality-Adjusted Life YearsThiophenesUnited Kingdom

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19513577

Citation

Borgström, F, et al. "The Cost-effectiveness of Strontium Ranelate in the UK for the Management of Osteoporosis." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 21, no. 2, 2010, pp. 339-49.
Borgström F, Ström O, Coelho J, et al. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int. 2010;21(2):339-49.
Borgström, F., Ström, O., Coelho, J., Johansson, H., Oden, A., McCloskey, E., & Kanis, J. A. (2010). The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 21(2), 339-49. https://doi.org/10.1007/s00198-009-0971-5
Borgström F, et al. The Cost-effectiveness of Strontium Ranelate in the UK for the Management of Osteoporosis. Osteoporos Int. 2010;21(2):339-49. PubMed PMID: 19513577.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. AU - Borgström,F, AU - Ström,O, AU - Coelho,J, AU - Johansson,H, AU - Oden,A, AU - McCloskey,E, AU - Kanis,J A, Y1 - 2009/06/10/ PY - 2009/01/15/received PY - 2009/04/21/accepted PY - 2009/04/17/revised PY - 2009/6/11/entrez PY - 2009/6/11/pubmed PY - 2011/1/14/medline SP - 339 EP - 49 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 21 IS - 2 N2 - UNLABELLED: The cost-effectiveness of strontium ranelate was compared to no treatment in UK women using the FRAX algorithm for fracture risk assessment. At a willingness-to-pay of pound 30,000 per quality-adjusted life-year (QALY), strontium ranelate was generally cost-effective in women with prior fracture at the threshold of osteoporosis from an age of 65 years. INTRODUCTION: The objectives of the study were to estimate the cost-effectiveness of strontium ranelate in the UK for the treatment of osteoporosis and to establish intervention thresholds for treatment using the FRAX tool. METHODS: The cost-effectiveness of strontium ranelate was compared to no treatment in postmenopausal women with clinical risk factors for fracture using a lifetime simulation model based on Markov cohort methodology that incorporated the features of FRAX. RESULTS: At a threshold of pound 30,000 per QALY, strontium ranelate was generally cost-effective in women from an age of 65 years with prior fracture at the threshold of osteoporosis (i.e., a T-score of -2.5 SD) and in women with a prior fracture (and no information on bone mineral density) from the age of 65 years. At a threshold of pound 20,000, strontium ranelate became cost-effective at a 10-year fracture probability of 25.7% and at 16.9% with a threshold of pound 30,000 for a QALY. CONCLUSIONS: Strontium ranelate is a cost-effective agent for the treatment of established osteoporosis in women over the age of 65 years. Cost-effective scenarios were also found for the prevention and treatment of fractures associated with osteoporosis, in younger women with additional clinical risk factors. SN - 1433-2965 UR - https://www.unboundmedicine.com/medline/citation/19513577/The_cost_effectiveness_of_strontium_ranelate_in_the_UK_for_the_management_of_osteoporosis_ L2 - https://doi.org/10.1007/s00198-009-0971-5 DB - PRIME DP - Unbound Medicine ER -